SCD1 inhibitor-3

Cat. No.: HY-139077

CAS No.: 1282606-48-7

Molecular Formula: $C_{19}H_{16}FN_7O_2$

Molecular Weight: 393.37

Target: Stearoyl-CoA Desaturase (SCD)

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1].

IC_{50} & Target

SCD1[1]

In Vivo

SCD1 inhibitor-3 (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1].

SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Lewis rats
Dosage:	5 mg/kg
Administration:	P.o.; 4 hours
Result:	Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.

Animal Model:	Lewis rats
Dosage:	2~10 mg/kg
Administration:	P.o.; 4 hours
Result:	A dose-responsive reduction of plasma triglycerides desaturation index.

REFERENCES

[1]. Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA